Scilex Reports Completion of Patient Enrollment in P-III C.L.E.A.R. Program for Semdexa (SP-102) to Treat Sciatica Pain Management

 Scilex Reports Completion of Patient Enrollment in P-III C.L.E.A.R. Program for Semdexa (SP-102) to Treat Sciatica Pain Management

Scilex Reports Completion of Patient Enrollment in P-III C.L.E.A.R. Program for Semdexa (SP-102) to Treat Sciatica Pain Management

Shots:

  • The company has completed the enrollment in the P-III C.L.E.A.R. program evaluating SP-102 vs PBO in 400 patients with lumbosacral radicular pain or sciatica at 40 sites across 25 states in the US. The results are expected in Q4’21
  • The 1EPs of the study is mean change in the numeric pain rating scale for leg pain @ 4 wks. Additionally, a trial is designed to assess 2EPs including other measures of pain i.e., back pain, time to repeat injection of SP-102, safety & function @ 4 & 12 wks.
  • If approved by the FDA, SP-102 would be the 1st non-opioid epidural injection for sciatica & will be available in a pre-filled syringe. The therapy also received FT designation from the FDA

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Scilex Holding

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post